BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 22228339)

  • 41. Optimization of scan initiation timing after
    Nakajima R; Abe K; Momose M; Fukushima K; Matsuo Y; Kimura K; Kondo C; Sakai S
    Ann Nucl Med; 2017 Feb; 31(2):190-197. PubMed ID: 27885545
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging.
    Sharma P; Kumar R; Singh H; Jeph S; Sharma JB; Jain SK; Sharma DN; Bal C; Malhotra A
    Nucl Med Commun; 2012 Feb; 33(2):185-90. PubMed ID: 22107993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of post-treatment metabolic tumor volume from
    Jung TY; Min JJ; Bom HS; Jung S; Kim IY; Lim SH; Kim DY; Kwon SY
    Neurosurg Rev; 2017 Apr; 40(2):223-229. PubMed ID: 27282449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
    J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures.
    Pirotte B; Goldman S; Dewitte O; Massager N; Wikler D; Lefranc F; Ben Taib NO; Rorive S; David P; Brotchi J; Levivier M
    J Neurosurg; 2006 Feb; 104(2):238-53. PubMed ID: 16509498
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
    Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 11C-Methionine Positron Emission Tomography/Computed Tomography Versus 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Evaluation of Residual or Recurrent World Health Organization Grades II and III Meningioma After Treatment.
    Tomura N; Saginoya T; Goto H
    J Comput Assist Tomogr; 2018; 42(4):517-521. PubMed ID: 29613985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A meta-analysis comparing 18F-FLT PET with 18F-FDG PET for assessment of brain tumor recurrence.
    Li Z; Yu Y; Zhang H; Xu G; Chen L
    Nucl Med Commun; 2015 Jul; 36(7):695-701. PubMed ID: 25768337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography.
    Utriainen M; Metsähonkala L; Salmi TT; Utriainen T; Kalimo H; Pihko H; Mäkipernaa A; Harila-Saari A; Jyrkkiö S; Laine J; Någren K; Minn H
    Cancer; 2002 Sep; 95(6):1376-86. PubMed ID: 12216107
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
    Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
    Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Utility of 11C-Methionine and 18F-FDG PET/CT in Patients With Functioning Pituitary Adenomas.
    Feng Z; He D; Mao Z; Wang Z; Zhu Y; Zhang X; Wang H
    Clin Nucl Med; 2016 Mar; 41(3):e130-4. PubMed ID: 26646998
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 99mTc-Methionine Hybrid SPECT/CT for Detection of Recurrent Glioma: Comparison With 18F-FDG PET/CT and Contrast-Enhanced MRI.
    Arora G; Sharma P; Sharma A; Mishra AK; Hazari PP; Biswas A; Garg A; Aheer D; Kumar R
    Clin Nucl Med; 2018 May; 43(5):e132-e138. PubMed ID: 29517540
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 13N-Ammonia PET/CT for detection of recurrent glioma: a prospective comparison with contrast-enhanced MRI.
    Khangembam BC; Sharma P; Karunanithi S; Singhal A; Das CJ; Kumar P; Julka PK; Bandopadhyaya GP; Kumar R; Malhotra A; Bal C
    Nucl Med Commun; 2013 Nov; 34(11):1046-54. PubMed ID: 24025920
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors.
    Schinkelshoek M; Lopci E; Clerici E; Alongi F; Mancosu P; Rodari M; Navarria P; van der Hiel B; Scorsetti M; Chiti A
    Tumori; 2014; 100(6):636-44. PubMed ID: 25688497
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
    Metser U; You J; McSweeney S; Freeman M; Hendler A
    AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the Outcome of Lung Nodules Missed on 18F-FDG PET/MRI Compared with 18F-FDG PET/CT in Patients with Known Malignancies.
    Sawicki LM; Grueneisen J; Buchbender C; Schaarschmidt BM; Gomez B; Ruhlmann V; Umutlu L; Antoch G; Heusch P
    J Nucl Med; 2016 Jan; 57(1):15-20. PubMed ID: 26514173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging.
    Manabe O; Hattori N; Yamaguchi S; Hirata K; Kobayashi K; Terasaka S; Kobayashi H; Motegi H; Shiga T; Magota K; Oyama-Manabe N; Nishijima K; Kuge Y; Tamaki N
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):896-904. PubMed ID: 25647076
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
    Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
    Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas.
    Tripathi M; Sharma R; D'Souza M; Jaimini A; Panwar P; Varshney R; Datta A; Kumar N; Garg G; Singh D; Grover RK; Mishra AK; Mondal A
    Clin Nucl Med; 2009 Dec; 34(12):878-83. PubMed ID: 20139821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.